Please use this identifier to cite or link to this item:
|Title:||Epidermal growth factor receptor (EGFR)-targeted therapies in Mesothelioma.|
|Authors:||Chia, Puey Ling;Scott, Andrew M;John, Thomas|
|Affiliation:||Faculty of Medicine, University of Melbourne, Melbourne, Australia|
School of Cancer Medicine, La Trobe University, Melbourne, Australia
Department of Molecular Imaging and Therapy, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
|Citation:||Expert opinion on drug delivery 2019; online first: 27 March|
|Abstract:||Malignant mesothelioma (MM) is an aggressive malignancy arising from the mesothelial cells lining the pleura and other serosal membranes. It is associated with an extremely poor prognosis and has limited therapeutic options. Areas covered: Epidermal growth factor receptor (EGFR) is known to be highly over-expressed in mesothelioma with reported EGFR overexpression between 44 to 97%. Given this, several anti-EGFR agents have been trialled in mesothelioma. In this review, we provide an overview of the current available data on anti-EGFR therapies in MM and future directions of investigation with these targeted agents in MM. Expert opinion: While many anti-EGFR therapies have failed to show significant efficacy in the management of MM, the pathway is biologically active and its abrogation preclinically points towards it being a valid target. Towards targeting the pathway, many novel EGFR based therapies are still being investigated. Current ongoing research of interest in MM include EGFR targeted nanotechnology approach for drug delivery, antibodies targeting the extracellular EGFR and potentially anti-EGFR antibody drug conjugates.|
epidermal growth factor receptor (EGFR)
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.